Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Illumina Inc.

3 Genomic Research Companies Pioneering Personalized Medicine

With vast potential, contribution to rare disease discovery and management, and adoption of AI, the genomic research market is thriving. Hence, fundamentally solid genomic research stocks Agilent Technologies (A), Illumina (ILMN), and 10x Genomics (TXG) could be ideal buys. Read more.

StockNews.com

3 Healthcare Stocks Innovating with AI

As healthcare rapidly advances, AI-driven technologies present compelling investment opportunities. Hence, investors might find promising potential in fundamentally solid healthcare stocks like Intuitive Surgical (ISRG), Illumina (ILMN), and Teladoc Health (TDOC). Keep reading.

StockNews.com

3 Biotech Stocks to Watch as FDA Approvals Roll In

The biotech sector is booming, fueled by rising healthcare demands, exciting advancements in technology, and increased FDA drug approvals. Thus, investing in Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), and Gilead Sciences (GILD) could be a golden opportunity for those looking to ride the wave of future breakthroughs. Read on….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Genomics Stocks Transforming Healthcare

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As this field rapidly evolves, investing in fundamentally sound genomics stocks like Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Illumina (ILMN) could be beneficial. Read more….

StockNews.com

3 Biotech Stocks With Anticipated Strong Earnings Reports

With highly effective drugs and treatment options, chronic disease prevalence, and adoption of technology, the biotech market is thriving. Hence, fundamentally solid biotech stocks Illumina (ILMN), Amgen (AMGN), and Entrada Therapeutics (TRDA) could be ideal with anticipated strong earnings reports. Read more.

StockNews.com

3 B-Rated Biotech Stocks to Boost Your Bottom Line

The biotech industry’s growth prospects look promising due to innovative drugs and therapies, government initiatives, and technological advancements. Therefore, investors could consider buying fundamentally strong biotech stocks BioMarin Pharmaceutical (BMRN), Illumina (ILMN), and Harmony Biosciences (HRMY). These stocks are B-rated (Buy) in our proprietary rating system. Read on.

StockNews.com

The biotech industry’s rapid expansion is driven by rising healthcare sending, groundbreaking innovations, and strategic collaborations, propelling the growth of biopharma companies. Thus, it could be wise to invest in popular biotech stocks Illumina (ILMN), Shionogi (SGIOY), and Regeneron Pharmaceuticals (REGN) for substantial gains. Keep reading….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stocks to Buy for Profits Beyond 2024

The biotech industry is expected to deliver steady returns amid rising medical needs and increased research and development investment. Therefore, fundamentally strong biotech stocks Illumina (ILMN), Innoviva (INVA) and Puma Biotechnology (PBYI) might be ideal additions to your portfolio. Read on.

StockNews.com

Will These 3 Biotech Stocks Make Gains in 2024?

In the swiftly progressing arena of biotechnology, technological advancements, increasing merger and acquisition maneuvers, and developing product pipelines are driving significant expansion in this sector. The sector's strong potential is further reinforced by a steady demand, ensuring its sustenance. Given this backdrop, let’s analyze whether or not biotech stocks Illumina…

StockNews.com

Why Illumina Shares Are Plunging Today?

A jury in the U.S. District Court for the District of Delaware rendered a verdict that Illumina Inc (NASDAQ:ILMN) willfully infringed the U.S. Patent Nos. 9,222,132 and 10,662,473 owned by Complete Genomics Inc. The jury awarded approximately $334 million to CGI in past damages. The jury also invalidated three patents owned by Illumina, namely, U.S.…

Benzinga

Illumina Reports 41% Dip In Q1 Profits Despite 12% Jump in Sales, Reaffirms FY22 Guidance

Illumina Inc's (NASDAQ:ILMN) Q1 FY22 revenues rose 12% Y/Y to $1.22 billion, in line with estimates. Nearly all revenues came from the core Illumina business; GRAIL, Illumina's cancer liquid biopsy subsidiary, recorded revenues of $10 million. Product revenue for the quarter totaled $1.07 billion, up 12%, and Service and other revenue amounted to…

Benzinga

FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis

The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was healthy. FDA issues warning on possible false results from noninvasive prenatal screening tests. The agency noted that these tests, also known as…

Benzinga

People

Kritika SarmahHer

714 stories

Sristi Suman JayaswalThe

216 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Regeneron Pharmaceuticals Inc

38 stories

BMRN

28 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.